Özet:

A severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is a zoonotic viral pathogen that belongs to the same family as the SARS-CoV family. Until now, in literature, there has been no report of a phenomenon taking mepolizumab treatment due to severe asthma and developing COVID-19. For the last 6 months for severe non-atopic asthma treatment, in addition to the existing asthma treatments, the 61 year old male patient who applied mepolizumab treatment, in September 2020 addressed our clinic with high fever, loss of smell and flavor developing in the last 3-4 days, drought cough and breathing difficulty complaints. In the patient's lungs tomography, ice-glass dancements were observed in the basal parts of both lungs and the patient's PCR result for SARS-CoV-2 was positive. The patient was treated with hydroxychlorokin, favipiravir and anticoagulant and the patient was taken to the quarantine at home. In their follow-up, the patient's complaints significantly relieved on the 5th day of treatment. While it is clear that the medications used in the treatment of severe asthma patients need broad and comprehensive studies to study their effects on COVID-19 infection, due to their anti-viral effectiveness, the positive contribution of mepolizumab to the treatment of COVID-19 infection should not be neglected and followed in this group of patients.

Anahtar Kelimeler: